Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ARHGAP44 and MYOCD antisense RNA 1 (ARHGAP44-AS1) is an RNA gene affiliated with the long non-coding RNA (lncRNA) class and does not code for a protein. This gene appears in genomic databases but lacks extensive functional or disease-role descriptions in current literature as of 2024. As a member of the lncRNA class, it is transcribed from the DNA strand opposite to the protein-coding ARHGAP44 locus. No published evidence currently describes its specific molecular function, biological role, or disease association. Its general class, lncRNA, is known to participate in gene regulation by interacting with chromatin, transcription factors, other RNAs, or the transcriptional machinery, but ARHGAP44-AS1 has not yet been clearly associated with such activity in scientific databases or literature. It is not considered a therapeutic target, nor are there drugs directly targeting it. No drugs are known to interact with it, and it is not reported as a biomarker or associated with any safety concerns due to its lack of known therapeutic or biomarker role. Note that ARHGAP44-AS1 is distinct from ARHGAP44, the protein-coding gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ARHGAP44 and MYOCD antisense RNA 1 (ARHGAP44-AS1).